AgomAb Therapeutics Series A

Contemporaneous report gives initial €21m Series A and participating investors; later company extension release corroborates €21m announced in April.

EUR 21,000,000 AmountApr 3, 2019 Announced

Source evidence

V-Bio Ventures
Active Belgian life sciences VC investing in biotech and drug development companies.

Something wrong or missing? Send an update. Fixed within 24 hours.